nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Adherence/Retention Alzheimer's Prevention Initiative Colombia Plan
|
Rios-Romenets, Silvia |
|
|
4 |
C |
p. 283-287 |
artikel |
2 |
Advances in functional magnetic resonance imaging data analysis methods using Empirical Mode Decomposition to investigate temporal changes in early Parkinson's disease
|
Cordes, Dietmar |
|
|
4 |
C |
p. 372-386 |
artikel |
3 |
Age stratification corrects bias in estimated hazard of APOE genotype for Alzheimer's disease
|
Liu, Li |
|
|
4 |
C |
p. 602-608 |
artikel |
4 |
Alzheimer's disease Archimedes condition-event simulator: Development and validation
|
Kansal, Anuraag R. |
|
|
4 |
C |
p. 76-88 |
artikel |
5 |
Alzheimer's disease drug development pipeline: 2018
|
Cummings, Jeffrey |
|
|
4 |
C |
p. 195-214 |
artikel |
6 |
Alzheimer's disease in Down syndrome: An overlooked population for prevention trials
|
Strydom, André |
|
|
4 |
C |
p. 703-713 |
artikel |
7 |
Amyloid-associated increases in longitudinal report of subjective cognitive complaints
|
Amariglio, Rebecca E. |
|
|
4 |
C |
p. 444-449 |
artikel |
8 |
A novel two-day intervention reduces stress in caregivers of persons with dementia
|
Spalding-Wilson, Kelsey N. |
|
|
4 |
C |
p. 450-460 |
artikel |
9 |
A randomized controlled trial of combined executive function and memory training on the cognitive and noncognitive function of individuals with mild cognitive impairment: Study rationale and protocol design
|
Zhang, Haifeng |
|
|
4 |
C |
p. 556-564 |
artikel |
10 |
A randomized, double-blind, placebo-controlled trial of resveratrol with glucose and malate (RGM) to slow the progression of Alzheimer's disease: A pilot study
|
Zhu, Carolyn W. |
|
|
4 |
C |
p. 609-616 |
artikel |
11 |
A randomized, single ascending dose study of intravenous BIIB092 in healthy participants
|
Qureshi, Irfan A. |
|
|
4 |
C |
p. 746-755 |
artikel |
12 |
A simulation study comparing slope model with mixed-model repeated measure to assess cognitive data in clinical trials of Alzheimer's disease
|
Chen, Yun-Fei |
|
|
4 |
C |
p. 46-53 |
artikel |
13 |
Biomedical informatics applications for precision management of neurodegenerative diseases
|
Miller, Justin B. |
|
|
4 |
C |
p. 357-365 |
artikel |
14 |
Bridging the gap: From reablement policy to practice for people with dementia
|
Poulos, Roslyn G. |
|
|
4 |
C |
p. 508-509 |
artikel |
15 |
Caregivers dying before care recipients with dementia
|
Gaugler, Joseph E. |
|
|
4 |
C |
p. 688-693 |
artikel |
16 |
Caregiving, intellectual disability, and dementia: Report of the Summit Workgroup on Caregiving and Intellectual and Developmental Disabilities
|
Heller, Tamar |
|
|
4 |
C |
p. 272-282 |
artikel |
17 |
Case-finding in clinical practice: An appropriate strategy for dementia identification?
|
Ranson, Janice M. |
|
|
4 |
C |
p. 288-296 |
artikel |
18 |
Central pharmacodynamic activity of solanezumab in mild Alzheimer's disease dementia
|
Willis, Brian A. |
|
|
4 |
C |
p. 652-660 |
artikel |
19 |
Cerebrospinal fluid neurogranin/β-site APP-cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer's disease
|
Kirsebom, Bjørn-Eivind |
|
|
4 |
C |
p. 617-627 |
artikel |
20 |
Clinical and cognitive characteristics of preclinical Alzheimer's disease in the Japanese Alzheimer's Disease Neuroimaging Initiative cohort
|
Ihara, Ryoko |
|
|
4 |
C |
p. 645-651 |
artikel |
21 |
Cognitive and structural cerebral changes in amnestic mild cognitive impairment due to Alzheimer's disease after multicomponent training
|
Teixeira, Camila Vieira Ligo |
|
|
4 |
C |
p. 473-480 |
artikel |
22 |
Community-based serious illness care for patients with dementia
|
Noah, Hannah |
|
|
4 |
C |
p. 324-325 |
artikel |
23 |
Computer Interactive Reminiscence and Conversation Aid groups—Delivering cognitive stimulation with technology
|
Astell, Arlene J. |
|
|
4 |
C |
p. 481-487 |
artikel |
24 |
Current understanding of magnetic resonance imaging biomarkers and memory in Alzheimer's disease
|
Bayram, Ece |
|
|
4 |
C |
p. 395-413 |
artikel |
25 |
Dietary intake of branched-chain amino acids in a mouse model of Alzheimer's disease: Effects on survival, behavior, and neuropathology
|
Tournissac, Marine |
|
|
4 |
C |
p. 677-687 |
artikel |
26 |
Dietary patterns and β-amyloid deposition in aging Australian women
|
Hill, Edward |
|
|
4 |
C |
p. 535-541 |
artikel |
27 |
Digital technologies as biomarkers, clinical outcomes assessment, and recruitment tools in Alzheimer's disease clinical trials
|
Gold, Michael |
|
|
4 |
C |
p. 234-242 |
artikel |
28 |
Discontinuation and nonpublication of interventional clinical trials conducted in patients with mild cognitive impairment and Alzheimer's disease
|
Yilmaz, Taygan |
|
|
4 |
C |
p. 161-164 |
artikel |
29 |
Donepezil may reduce the risk of comorbidities in patients with Alzheimer's disease: A large-scale matched case-control analysis in Japan
|
Kobayashi, Hiroyuki |
|
|
4 |
C |
p. 130-136 |
artikel |
30 |
Effect of donepezil on transcranial magnetic stimulation parameters in Alzheimer's disease
|
Hwang, Yun Tae |
|
|
4 |
C |
p. 103-107 |
artikel |
31 |
Effects of sex, educational background, and chronic kidney disease grading on longitudinal cognitive and functional decline in patients in the Japanese Alzheimer's Disease Neuroimaging Initiative study
|
Iwata, Atsushi |
|
|
4 |
C |
p. 765-774 |
artikel |
32 |
Efficacy and safety of the compound Chinese medicine SaiLuoTong in vascular dementia: A randomized clinical trial
|
Jia, Jianping |
|
|
4 |
C |
p. 108-117 |
artikel |
33 |
Electrical brain stimulation in different variants of primary progressive aphasia: A randomized clinical trial
|
Tsapkini, Kyrana |
|
|
4 |
C |
p. 461-472 |
artikel |
34 |
Elevated phospholipase D isoform 1 in Alzheimer's disease patients' hippocampus: Relevance to synaptic dysfunction and memory deficits
|
Krishnan, Balaji |
|
|
4 |
C |
p. 89-102 |
artikel |
35 |
Established amyloid-β pathology is unaffected by chronic treatment with the selective serotonin reuptake inhibitor paroxetine
|
Severino, Maurizio |
|
|
4 |
C |
p. 215-223 |
artikel |
36 |
Feasibility and efficacy data from a ketogenic diet intervention in Alzheimer's disease
|
Taylor, Matthew K. |
|
|
4 |
C |
p. 28-36 |
artikel |
37 |
From information to follow-up: Ethical recommendations to facilitate the disclosure of amyloid PET scan results in a research setting
|
Vanderschaeghe, Gwendolien |
|
|
4 |
C |
p. 243-251 |
artikel |
38 |
Galectin-3 and incident cognitive impairment in REGARDS, a cohort of blacks and whites
|
Venkatraman, Anand |
|
|
4 |
C |
p. 165-172 |
artikel |
39 |
Hearing treatment for reducing cognitive decline: Design and methods of the Aging and Cognitive Health Evaluation in Elders randomized controlled trial
|
Deal, Jennifer A. |
|
|
4 |
C |
p. 499-507 |
artikel |
40 |
Highly specific and selective anti-pS396-tau antibody C10.2 targets seeding-competent tau
|
Rosenqvist, Nina |
|
|
4 |
C |
p. 521-534 |
artikel |
41 |
Impact of apolipoprotein E genotypes on vitamin E and memantine treatment outcomes in Alzheimer's disease
|
Belitskaya-Lévy, Ilana |
|
|
4 |
C |
p. 344-349 |
artikel |
42 |
Inflammation as a central mechanism in Alzheimer's disease
|
Kinney, Jefferson W. |
|
|
4 |
C |
p. 575-590 |
artikel |
43 |
Intranasal rifampicin for Alzheimer's disease prevention
|
Umeda, Tomohiro |
|
|
4 |
C |
p. 304-313 |
artikel |
44 |
Lifestyle and neurodegeneration in midlife as expressed on functional magnetic resonance imaging: A systematic review
|
Topiwala, Hinesh |
|
|
4 |
C |
p. 182-194 |
artikel |
45 |
Longitudinal patterns of potentially inappropriate medication use following incident dementia diagnosis
|
Ramsey, Christine M. |
|
|
4 |
C |
p. 1-10 |
artikel |
46 |
Measuring cognition and function in the preclinical stage of Alzheimer's disease
|
Weintraub, Sandra |
|
|
4 |
C |
p. 64-75 |
artikel |
47 |
Minimotifs dysfunction is pervasive in neurodegenerative disorders
|
Sharma, Surbhi |
|
|
4 |
C |
p. 414-432 |
artikel |
48 |
Network-based assessment of collaborative research in neuroscience
|
Marchand, Gwen C. |
|
|
4 |
C |
p. 433-443 |
artikel |
49 |
Neural correlates of episodic memory in the Memento cohort
|
Epelbaum, Stephane |
|
|
4 |
C |
p. 224-233 |
artikel |
50 |
Neurodegeneration research: Advances in clinical translational neuroscience infrastructure and methods
|
Cummings, Jeffrey L. |
|
|
4 |
C |
p. 326-329 |
artikel |
51 |
Neuroimaging and neuropsychological assessment of freezing of gait in Parkinson's disease
|
Bluett, Brent |
|
|
4 |
C |
p. 387-394 |
artikel |
52 |
Neuroprotective effect of a new photobiomodulation technique against Aβ25–35 peptide–induced toxicity in mice: Novel hypothesis for therapeutic approach of Alzheimer's disease suggested
|
Blivet, Guillaume |
|
|
4 |
C |
p. 54-63 |
artikel |
53 |
Neuroscience learning from longitudinal cohort studies of Alzheimer's disease: Lessons for disease-modifying drug programs and an introduction to the Center for Neurodegeneration and Translational Neuroscience
|
Ritter, Aaron |
|
|
4 |
C |
p. 350-356 |
artikel |
54 |
Nuclear factor-kappa B: Glucocorticoid-induced leucine zipper interface analogs suppress pathology in an Alzheimer's disease model
|
Srinivasan, Mythily |
|
|
4 |
C |
p. 488-498 |
artikel |
55 |
Objectively measured physical activity profile and cognition in Finnish elderly twins
|
Iso-Markku, Paula |
|
|
4 |
C |
p. 263-271 |
artikel |
56 |
Online study partner-reported cognitive decline in the Brain Health Registry
|
Nosheny, Rachel L. |
|
|
4 |
C |
p. 565-574 |
artikel |
57 |
Opioid use and the presence of Alzheimer's disease and related dementias among elderly Medicare beneficiaries diagnosed with chronic pain conditions
|
Shen, Chan |
|
|
4 |
C |
p. 661-668 |
artikel |
58 |
Participant outcomes and preferences in Alzheimer's disease clinical trials: The electronic Person-Specific Outcome Measure (ePSOM) development program
|
Saunders, Stina |
|
|
4 |
C |
p. 694-702 |
artikel |
59 |
Patient perspectives of the experience of a computerized cognitive assessment in a clinical setting
|
Robillard, Julie M. |
|
|
4 |
C |
p. 297-303 |
artikel |
60 |
Person-centered care for older people with dementia in the acute hospital
|
Tay, Felicia Hui En |
|
|
4 |
C |
p. 19-27 |
artikel |
61 |
Racial and ethnic differences in trends in dementia prevalence and risk factors in the United States
|
Chen, Cynthia |
|
|
4 |
C |
p. 510-520 |
artikel |
62 |
Randomized, controlled, proof-of-concept trial of MK-7622 in Alzheimer's disease
|
Voss, Tiffini |
|
|
4 |
C |
p. 173-181 |
artikel |
63 |
Simultaneously evaluating the effect of baseline levels and longitudinal changes in disease biomarkers on cognition in dominantly inherited Alzheimer's disease
|
Wang, Guoqiao |
|
|
4 |
C |
p. 669-676 |
artikel |
64 |
Statistical advances in clinical trials and clinical research
|
Shan, Guogen |
|
|
4 |
C |
p. 366-371 |
artikel |
65 |
Synergism of antihypertensives and cholinesterase inhibitors in Alzheimer's disease
|
Hu, Ziheng |
|
|
4 |
C |
p. 542-555 |
artikel |
66 |
“Text It” program to track falls in patients with Alzheimer's disease and dementia
|
Kamil, Rebecca J. |
|
|
4 |
C |
p. 137-140 |
artikel |
67 |
The Age-Well observational study on expert meditators in the Medit-Ageing European project
|
Lutz, Antoine |
|
|
4 |
C |
p. 756-764 |
artikel |
68 |
The Age-Well randomized controlled trial of the Medit-Ageing European project: Effect of meditation or foreign language training on brain and mental health in older adults
|
Poisnel, Géraldine |
|
|
4 |
C |
p. 714-723 |
artikel |
69 |
The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier cohort
|
Tariot, Pierre N. |
|
|
4 |
C |
p. 150-160 |
artikel |
70 |
The Cognitive Ageing, Nutrition and Neurogenesis (CANN) trial: Design and progress
|
Irvine, Michael A. |
|
|
4 |
C |
p. 591-601 |
artikel |
71 |
The hidden variables problem in Alzheimer's disease clinical trial design
|
Liyanage, S. Imindu |
|
|
4 |
C |
p. 628-635 |
artikel |
72 |
The influence of GAPT extraction on synapse loss of APPswe/PS1dE9 transgenic mice via adjusting Bcl-2/Bax balance
|
Shi, Jing |
|
|
4 |
C |
p. 724-736 |
artikel |
73 |
The My Active and Healthy Aging (My-AHA) ICT platform to detect and prevent frailty in older adults: Randomized control trial design and protocol
|
Summers, Mathew J. |
|
|
4 |
C |
p. 252-262 |
artikel |
74 |
The price of progress: Funding and financing Alzheimer's disease drug development
|
Cummings, Jeffrey |
|
|
4 |
C |
p. 330-343 |
artikel |
75 |
The SCD-Well randomized controlled trial: Effects of a mindfulness-based intervention versus health education on mental health in patients with subjective cognitive decline (SCD)
|
Marchant, Natalie L. |
|
|
4 |
C |
p. 737-745 |
artikel |
76 |
TOMMORROW neuropsychological battery: German language validation and normative study
|
Romero, Heather R. |
|
|
4 |
C |
p. 314-323 |
artikel |
77 |
Translational inhibition of APP by Posiphen: Efficacy, pharmacodynamics, and pharmacokinetics in the APP/PS1 mouse
|
Teich, Andrew F. |
|
|
4 |
C |
p. 37-45 |
artikel |
78 |
Unmasking the benefits of donepezil via psychometrically precise identification of mild cognitive impairment: A secondary analysis of the ADCS vitamin E and donepezil in MCI study
|
Edmonds, Emily C. |
|
|
4 |
C |
p. 11-18 |
artikel |
79 |
User experience and clinical effectiveness with two wearable global positioning system devices in home dementia care
|
Megges, Herlind |
|
|
4 |
C |
p. 636-644 |
artikel |
80 |
Virtual reality-based cognitive-motor training for middle-aged adults at high Alzheimer's disease risk: A randomized controlled trial
|
Doniger, Glen M. |
|
|
4 |
C |
p. 118-129 |
artikel |
81 |
Wishes and preferences for an online lifestyle program for brain health—A mixed methods study
|
Wesselman, Linda M.P. |
|
|
4 |
C |
p. 141-149 |
artikel |